Karen E. Knudsen's profile picture

Karen E. Knudsen

Dr. Knudsen is the Director of the Sidney Kimmel Cancer Center and the Hilary Koprowski Chair of the Department of Cancer Biology at Thomas Jefferson University. Dr. Knudsen’s research focuses on androgen receptor (AR) signaling in prostate cancer, to delineate the molecular mechanisms driving androgen dependence. Her research identifying tumor suppressor and hormone receptor alterations has revealed novel targets for treating this disease, leading to biomarker-driven clinical trials. Dr. Knudsen also has joint appointments in the Departments of Urology, Radiation Oncology, and Medical Oncology. Additionally, she served as the first Vice Provost for Thomas Jefferson University, overseeing and integrating basic and clinical research across the colleges.


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


A

Atrin Pharmaceuticals

Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.


Employees

1-10

Links